Shen ding logo
Shen ding
Generic APIs

Degarelix acetate,214766-78-6

Degarelix acetate,214766-78-6
  • CAS#:214766-78-6
  • Product Name:Degarelix acetate
  • Size:1g or more
  • Supply Ability:500g/two weeks
  • FOB Price:Email
  • Payment Terms:T/T
  • Lead time:Within 12 hours after receiving payment
  • Packing:Discreet ways of packing for Customs pass guaranteed
  • Delivery:by express (FedEx,UPS,DHL,EMS), by air
  • Download:MSDS
  • Contact Now
  • Specification
  • MSDS
  • Reviews

Scipeptide is a professional Manufacturer, Supplier & Exporter of Degarelix acetate for the pharmaceutical market,Supply Ability:500g/two weeks,we make sure to check this Degarelix acetate chemical on standard quality parameters.

Degarelix acetate-Physiochemical properties

      Sequence(Single-Letter Code):

      Sequence(Three-Letter Code): Ac-D-2-Nal-D-Phe(4-Cl)-D-3-Pal-Ser-4-Aph(Hor)-D-4-Aph(Cbm)-Leu-Lys(ipr)-Pro-D-Ala-NH2

      Number of residues:     10aa

      Molecular weight:     1630.75g/mol

      Extinction coefficient: 0 M-1cm-1

      Iso-electric point:    

      Net charge at pH 7:    

      Estimated solubility:     Poor water solubility.

      Storage:store in cool, dry, ventilated place

      PSA:     512.87000

      LogP:     7.56580

      ATC code:L02BX02

      PubChem     CID: 16186010

      IUPHAR/BPS:5585

      DrugBank:DB06699

      UNII:SX0XJI3A11

      KEGG:D08901

      ChEMBL:264089

Degarelix acetate Description

      Alternate Names:DEGARELIX;Degarelix acetate;N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-4-[2,6-dioxohexahydropyrimidin-4(S)-ylcarboxamido]-L-phenylalanyl-4-ureido-D-phenylalanyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamide acetate;D-Alaninamide, N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-;Degarelix acetate(FE-200486,Degarelix);FirMagon

Degarelix is a man-made form of a protein that reduces the amount of certain hormones in the body, including testosterone.
Degarelix Acetate is an LHRH (GnRH) receptor antagonist, indicated for patients with advanced prostate cancer. Degarelix reversibly and dose-dependently suppresses gonadotropin and sex steroid levels by inhibiting the binding of endogenous LHRH to its receptors.
Degarelix showed to be at least as effective as leuprolide in sustaining levels of testosterone that are equivalent to or lower than that seen with castration. Degarelix or degarelix acetate(Firmagon) is a hormonal therapy used in the treatment of prostate cancer. During development it was known as FE200486.
Degarelix is a synthetic linear decapeptide amide containing seven unnatural amino acids, five of which are D-amino acids. The acetate salt of degarelix is a white to off-white amorphous powder of low density as obtained after lyophilization.

Degarelix acetate Application

Degarelix is used to treat prostate cancer.Advanced hormone-dependent prostate carcinoma.

Degarelix acetate References

1,Princivalle M, Broqua P, White R, et al (March 2007). Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist. J. Pharmacol. Exp. Ther. 320: 1113-8.
2,PR Newswire. FDA approves Ferring Pharmaceuticals' Degarelix (generic name) for the treatment of advanced prostate cancer. PR Newswire, Europe Ltd 2008 [cited 2009 Mar 2]; Available from here
3,Van Poppel H, Nilsson S (June 2008). Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology 71: 1001-6.
4,Klotz L, Boccon-Gibod L, Shore ND, et al (December 2008). The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 102: 1531-8.
5,Schröder FH, Boccon-Gibod L, Tombal B, et al (March 2009) Degarelix versus leuprolide in patients with prostate cancer: effect in metastatic patients as assessed by serum alkaline phosphatase. European Association of Urology (EAU) Annual congress 17–21 March 2009, Stockholm, Sweden. Abstract 40.



If not, Please tell me about your specific sequence. We provide the custom peptide synthesis for you.

Online Inquiry

Please feel free to give your inquiry in the form below.We will reply you in 24 hours.

  •  
return top